CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).

Julien Edeline,Thomas Yau,Joong Won Park,Masatoshi Kudo,Kwang Hyub Han,Philippe Mathurin,Philippe Merle,Richard S. Finn,Tobias Müller,Fiona Taylor,Mike Greenwood,Damir Begic,Marina Tschaika,Christine Yip,Emma Pranschke,Kim Cocks,Gwilym Thompson,Steven I Blum,T Wisniewski,Bruno Sangro

CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).

2020

483Background: SOR is approved as 1L therapy for pts with aHCC, but there is still an unmet need to help improve or maintain HRQoL. This phase 3 study compared HRQoL of NIVO vs SOR as 1L therapy in...

Keywords:

Hepatocellular carcinoma
Sorafenib
first line
Quality of life
Internal medicine
Nivolumab
Checkmate
Medicine
Physical therapy
Oncology
health related quality of life
in patient
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations